AZD0516 / AstraZeneca - LARVOL DELTA

AZD0516: Data from P1/2 SEACLIFF trial (NCT07181161) for mCRPC post 2026 (AstraZeneca) - Q3 2025 Results

P1/2 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer

SEACLIFF: Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer (clinicaltrials.gov) - P1/2 | N=177 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • Monotherapy • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • STEAP1

SEACLIFF: Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer (clinicaltrials.gov) - P1/2 | N=177 | Not yet recruiting | Sponsor: AstraZeneca

Monotherapy • New P1/2 trial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • STEAP1

Preclinical characterization of AZD0516, a novel STEAP2 antibody-drug conjugate (ADC) for the treatment of prostate cancer (AACR 2025) - "Safety findings included hematological and gastrointestinal effects, consistent with the MoA and known effects of TOP1i payloads. Together, these data support exploring AZD0516 clinically for patients with mCRPC."

Preclinical • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • STEAP1 • STEAP2